Adimab LLC. Announces New Discovery Collaboration ith Kyowa Hakko Kirin
Published: Jan 07, 2013
LEBANON, N.H.--(BUSINESS WIRE)--Adimab, LLC, a technology leader in the discovery of fully human antibodies, today announced a two-target funded discovery collaboration with Kyowa Hakko Kirin (KHK) of Tokyo, Japan. Based on the strength and flexibility of Adimab’s platform, KHK has designated a membrane protein target as the initial collaboration target. In addition, Adimab announced the receipt of milestone payments from its existing collaborations with Gilead, Biogen Idec and Novo Nordisk.